In a strategic move for the biotechnology and healthcare diagnostics industry, MedGenome announced a majority investment in Green Cross Genetics Lab. 

Through this investment, MedGenome will strengthen its presence in Gujarat. It will leverage Green Cross’s local network, reputation and infrastructure. While Green Cross will gain access to MedGenome’s genomic testing, AI/ML-enabled pipelines, and broader diagnostics portfolio.

Notably, Green Cross started with a small laboratory in Ahmedabad’s Paldi area. It has now expanded to almost 20000 sq. ft. area in Gujarat. It has become one of the leading laboratories in Gujarat, operating for more than three decades. Today, it has 17 laboratories and 35 collection centres in Gujarat. It offers more than 800 diagnostic solutions. 

Vinod Patel, Promoter & Director, Green Cross Genetics Lab, on the partnership said, “We are excited to partner with MedGenome, a leader in genomic testing, to expand our diagnostics service offerings. Our companies have a rich legacy of trust and quality, and this partnership will combine our strengths across infrastructure, technology, distribution, and clinical expertise. Combining our extensive portfolio of over 800 diagnostics solutions and a dedicated team of 500 employees, with MedGenome’s world-class genomics capabilities, we can offer a more comprehensive menu of services across the country. The collaboration also enables more efficient integration of genomics into diagnostics, unlocking new opportunities to service our clinicians and patient base.”

MedGenome, meanwhile, is a genomics-driven diagnostics and research services company. It claims to have sequenced over 500,000 exomes and genomes in the past decade. Additionally, it operates the largest CAP-accredited genetic testing laboratory in South Asia.

Dr. Vedam Ramprasad, CEO, MedGenome, said, “This partnership will strengthen MedGenome’s market presence in Gujarat, allowing us to better serve a broader population. It reiterates our commitment to improving access to affordable omics solutions, particularly in Tier 2 and Tier 3 cities. With Green Cross’s three-decade legacy of trust and high-quality diagnostics, this partnership perfectly aligns with our mission to harness genomics for early, accurate disease detection and management. As we work towards positioning Indian genomics on the global stage, we will continue to innovate and create solutions that meet the needs of diverse markets worldwide.”

Incidentally, Gujarat has pursued industrial excellence, infrastructure investment and manufacturing growth for a long time. This partnership can help Gujarat to position itself in emerging high-value health and biotech services.

Gujarat To Gain Improved Access To Genomics And Diagnostics

Gujarat already has a growing healthcare ecosystem. But advanced genomics diagnostics are concentrated in the metropolitan area. However, with MedGenome investing in a local lab, that access can be widely distributed across states. It will also bring a lot of impact into tier-2 and tier-3 cities. 

Once it becomes more accessible to local patients, their travel cost will reduce. Moreover, it will help to detect a disease early and in creating personalised medical options which were previously less accessible. 

Notably, Green Cross already has a significant infrastructure in the state. It includes multiple labs, collection centres, and a track record of reliability in Gujarat. The infusion of genomic capabilities will make Gujarat’s ecosystem more sophisticated. It will attract medical-technology investment, stimulate local supply chains, and raise the state’s profile in life-sciences. 

Skill Development And Economic Multiplier

As the diagnostics operations scale with genomics, more skilled labourers will be required. It will be in the form of lab technicians, bioinformaticians, genetic counsellors, AI/data-pipeline engineers, quality assurance staff, etc. Having major operations based in Gujarat will mean more local employment. Over time, it will help to build a more capable health-science workforce in the state.

Health-tech and biotech sectors will help industrial development in adjacent sectors. There could be research collaborations with medical colleges, hospitals, and universities in Gujarat. It might also attract more venture capitalists and grants from the government. All of this will contribute to the state’s broader economic diversification and innovation profile.

Challenges And Considerations 

While the investment looks promising, there might be some challenges. Advanced genomics tests are very expensive. Ensuring it becomes affordable to a broad population will be the key. MedGenome has signalled a commitment to “affordable omics solutions”. But its implementation will matter. 

To fully benefit, Gujarat will need ancillary facility. It includes reliable logistics for sample collection and transport from remote areas. The Green Cross network will come in handy here, but scaling into more rural districts may require additional support. Encouraging partnerships with Gujarat’s universities, medical colleges, research centres will help in the cause. 

Conclusion

For Gujarat, the major investment by MedGenome is more than a business deal. MedGenome and Green Cross might help to shape Gujarat’s next chapter in leveraging diagnostics footprint and infrastructure. It could be a compelling example of how a state can frontier the healthcare sector. And we at Gujpreneur will keep a close eye at any other development from this sector.